MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412954 | Name: Cisatracurium (free base)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cisatracurium (free base) is an intermediate-duration, non-depolarising neuromuscular blocking agent for intravenous administration. Cisatracurium is indicated for use during surgical and other procedures and in intensive care in adults and children aged 1 month and over.

Chemical Structure

Cisatracurium (free base)
Cisatracurium (free base)
CAS#96946-41-7 (free base)

Theoretical Analysis

MedKoo Cat#: 412954

Name: Cisatracurium (free base)

CAS#: 96946-41-7 (free base)

Chemical Formula: C53H72N2O122+

Exact Mass: 928.5074

Molecular Weight: 929.16

Elemental Analysis: C, 68.51; H, 7.81; N, 3.01; O, 20.66

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
64228-81-5 (besylate_mixture of isomers) 96946-41-7 (free base) 96946-42-8 (besylate)
Synonym
Cisatracurium (free base)
IUPAC/Chemical Name
(1R,1'R,2R,2'R)-2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium)
InChi Key
YXSLJKQTIDHPOT-LJCJQEJUSA-N
InChi Code
InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2/t42-,43-,54-,55-/m1/s1
SMILES Code
C[N@@+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N@+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C=C6)OC)OC)OC)OC)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 929.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Strawbridge AD, Khanna NR, Hauser JM. Cisatracurium. 2020 Jul 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 30969664. 2: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Cisatracurium. 2020 Nov 16. PMID: 29999740. 3: Lim J, Cox J, Nguyen T, Arya R. Cisatracurium dosing in a patient with hyperthermia. Am J Health Syst Pharm. 2019 Jul 2;76(14):1029-1032. doi: 10.1093/ajhp/zxz098. PMID: 31361873. 4: Sottile PD, Kiser TH, Burnham EL, Ho PM, Allen RR, Vandivier RW, Moss M; Colorado Pulmonary Outcomes Research Group (CPOR). An Observational Study of the Efficacy of Cisatracurium Compared with Vecuronium in Patients with or at Risk for Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2018 Apr 1;197(7):897-904. doi: 10.1164/rccm.201706-1132OC. PMID: 29241014; PMCID: PMC6020402. 5: National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Moss M, Huang DT, Brower RG, Ferguson ND, Ginde AA, Gong MN, Grissom CK, Gundel S, Hayden D, Hite RD, Hou PC, Hough CL, Iwashyna TJ, Khan A, Liu KD, Talmor D, Thompson BT, Ulysse CA, Yealy DM, Angus DC. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome. N Engl J Med. 2019 May 23;380(21):1997-2008. doi: 10.1056/NEJMoa1901686. Epub 2019 May 19. PMID: 31112383; PMCID: PMC6741345. 6: Che D, Rui L, Cao J, Wang J, Zhang Y, Ding Y, Zhao T, Ma P, An H, Gao Z, Zhang T. Cisatracurium induces mast cell activation and pseudo-allergic reactions via MRGPRX2. Int Immunopharmacol. 2018 Sep;62:244-250. doi: 10.1016/j.intimp.2018.07.020. Epub 2018 Jul 20. PMID: 30032049. 7: Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Arnal JM, Perez D, Seghboyan JM, Constantin JM, Courant P, Lefrant JY, Guérin C, Prat G, Morange S, Roch A; ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010 Sep 16;363(12):1107-16. doi: 10.1056/NEJMoa1005372. PMID: 20843245. 8: Ortiz JR, Percaz JA, Carrascosa F. Cisatracurio [Cisatracurium]. Rev Esp Anestesiol Reanim. 1998 Jun-Jul;45(6):242-7. Spanish. PMID: 9719722. 9: Merkel A, Massey K, Bellamy C, Miano T, Fuchs B, Candeloro C. Predictors of Cisatracurium Continuous Infusion Dose in Acute Respiratory Distress Syndrome. J Pharm Pract. 2019 Nov 18:897190019888103. doi: 10.1177/0897190019888103. Epub ahead of print. PMID: 31736402. 10: Szakmany T, Woodhouse T. Use of cisatracurium in critical care: a review of the literature. Minerva Anestesiol. 2015 Apr;81(4):450-60. Epub 2014 Apr 10. PMID: 24721895.